<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902018000100078</article-id>
<article-id pub-id-type="doi">10.29262/ram.v65i1.315</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Enfermedad respiratoria exacerbada por aspirina. Revisión a partir de casos clínicos]]></article-title>
<article-title xml:lang="en"><![CDATA[Aspirin-exacerbated respiratory disease. Case-based review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Moreno]]></surname>
<given-names><![CDATA[Karen Estefanía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cardona]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<volume>65</volume>
<numero>1</numero>
<fpage>78</fpage>
<lpage>91</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902018000100078&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902018000100078&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902018000100078&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La enfermedad respiratoria exacerbada por aspirina comprende un conjunto de signos y síntomas que involucran principalmente la vía aérea superior e inferior posterior al consumo de inhibidores de la enzima ciclooxigenasa. Las reacciones adversas que se presentan no se consideran una alergia y son comunes a todos los antiinflamatorios no esteroideos, por lo que la reactividad cruzada entre estos es común. La descripción de tres casos clínicos con diferentes situaciones sirve para revisar aspectos clave de la enfermedad como la epidemiologia, fisiopatología, manifestaciones clínicas, diagnóstico y manejo. El adecuado diagnóstico y educación en el uso o eliminación de los diferentes AINE es fundamental, al igual que la disposición de opciones analgésicas alternativas, comprobadas mediante pruebas de provocación. El manejo de la enfermedad respiratoria exacerbada por aspirina incluye procedimientos quirúrgicos para el control de los pólipos nasales, tratamiento farmacológico para el control del asma y desensibilización con aspirina en individuos seleccionados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Aspirin-exacerbated respiratory disease comprises a series of signs and symptoms mainly involving the upper and lower posterior airway after the consumption of cyclooxygenase enzyme inhibitors. Adverse reactions that occur are not considered to be an allergy and are common to all non-steroidal anti-inflammatory drugs, and cross-reactivity between these agents is therefore common. The description of 3 clinical cases serves to review key aspects of this condition, such as epidemiology, pathophysiology, clinical manifestations, diagnosis and management. Adequate diagnosis and education on the use or elimination of all different NSAIDs is essential, as well as availability of different analgesic options, verified with challenge tests. Aspirin-exacerbated respiratory disease management includes surgical procedures for nasal polyp control, pharmacological treatment for asthma control and desensitization with aspirin in selected individuals.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Reacción de hipersensibilidad]]></kwd>
<kwd lng="es"><![CDATA[Enzima ciclooxigenasa]]></kwd>
<kwd lng="es"><![CDATA[Antinflamatorio no esteroideo]]></kwd>
<kwd lng="es"><![CDATA[Rinosinusitis crónica]]></kwd>
<kwd lng="es"><![CDATA[Asma]]></kwd>
<kwd lng="es"><![CDATA[Pólipos nasales]]></kwd>
<kwd lng="es"><![CDATA[Desensibilización a la aspirina]]></kwd>
<kwd lng="en"><![CDATA[Hypersensitivity reaction]]></kwd>
<kwd lng="en"><![CDATA[Cyclooxygenase enzyme]]></kwd>
<kwd lng="en"><![CDATA[Non-steroidal anti-inflammatory drug]]></kwd>
<kwd lng="en"><![CDATA[Chronic rhinosinusitis]]></kwd>
<kwd lng="en"><![CDATA[Asthma]]></kwd>
<kwd lng="en"><![CDATA[Nasal polyps]]></kwd>
<kwd lng="en"><![CDATA[Aspirin desensitization]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakalar]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Muluk]]></surname>
<given-names><![CDATA[NB]]></given-names>
</name>
<name>
<surname><![CDATA[Kar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cingi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory disease and current treatment modalities]]></article-title>
<source><![CDATA[Eur Arch Otorhinolaryngol]]></source>
<year>2017</year>
<volume>274</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1292-300</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laidlaw]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[JA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory diseas-new prime suspects]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>484-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinke]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Negri]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Borish]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin activation of eosinophils and mast cells: Implications in the pathogenesis of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2014</year>
<volume>193</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Szczeklik]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and pathologic perspectives on aspirin sensitivity and asthma]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2006</year>
<volume>118</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>773-86</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beers]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intolerance to aspirin. Clinical studies and consideration of its Pathogenesis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1968</year>
<volume>68</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>975-83</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2017</year>
<volume>139</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>764-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mullol]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Picado]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Immunol Allergy Clin NA]]></source>
<year>2017</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>163-76</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Castells]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Gawchik]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Settipane]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin challenge and desensitization for aspirin- exacerbated respiratory disease: A practice paper]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2007</year>
<volume>98</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>172-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laidlaw]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current knowledge and management of hypersensitivity to aspirin and NSAIDs]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2017</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>537-45</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jares]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Borges]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ensina]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Arias-Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multinational experience with hypersensitivity drug reactions in Latin America]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2014</year>
<volume>113</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>282-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajan]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Wineinger]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[AA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2015</year>
<volume>135</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>676-81</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsch]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Nordberg]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Mercer]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2017</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1061-70</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vento]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Ertama]]></surname>
<given-names><![CDATA[LO]]></given-names>
</name>
<name>
<surname><![CDATA[Hytönen]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Malmberg]]></surname>
<given-names><![CDATA[CH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nasal polyposis: Clinical course during 20 years]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2000</year>
<volume>85</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>209-14</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Settipane]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Chafee]]></surname>
<given-names><![CDATA[FH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nasal polyps in asthma and rhinitis. A review of 6,037 patients]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>1977</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Laidlaw]]></surname>
<given-names><![CDATA[TM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis of aspirin-induced reactions in aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am]]></source>
<year>2016</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>681-91</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ayars]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipid mediators in aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am]]></source>
<year>2016</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>749-63</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christie]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Tagari]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ford-hutchinson]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects 1-3]]></article-title>
<source><![CDATA[Am Rev Respir Dis]]></source>
<year>1990</year>
<volume>143</volume>
<page-range>1025-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Burnett]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Katial]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of benefit with aspirin therapy in aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am]]></source>
<year>2016</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>735-47</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cowburn]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Sladek]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Soja]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Adamek]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Austen]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1998</year>
<volume>101</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>834-46</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Tozzi]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Malice]]></surname>
<given-names><![CDATA[MP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation]]></article-title>
<source><![CDATA[Thorax]]></source>
<year>2004</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>100-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kanaoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Maekawa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Austen]]></surname>
<given-names><![CDATA[KF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2013</year>
<volume>288</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>10967-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bankova]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshimoto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Austen]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Kanaoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2016</year>
<volume>113</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>6242-7</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monneret]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gravel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rokach]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[WS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2001</year>
<volume>98</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1942-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Bensko]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Laidlaw]]></surname>
<given-names><![CDATA[TM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostaglandin D2: A dominant mediator of aspirin exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2016</year>
<volume>135</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>245-52</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kanaoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Barrett]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boyce]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2015</year>
<volume>195</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>3537-45</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buchheit]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lee-Sarwar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2017</year>
<volume>137</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1566-76</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laidlaw]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Kidder]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Bhattacharyya]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Milne]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>119</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>3790-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitsui]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kajiwara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ono]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2016</year>
<volume>137</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>400-11</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Celik]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Schroeder]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adkinson]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Clin Exp Allergy]]></source>
<year>2010</year>
<volume>39</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1522-31</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[RU]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dursun]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Woessner]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2010</year>
<volume>105</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>130-5</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berges-Gimeno]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The natural history and clinical characteristics of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2002</year>
<volume>89</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>474-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graefe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Roebke]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[JE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin sensitivity and chronic rhinosinusitis with polyps : a fatal combination]]></article-title>
<source><![CDATA[J Allergy (Cairo)]]></source>
<year>2012</year>
<volume>2012</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>817-910</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bachert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Canonica]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Lockey]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unmet needs in severe chronic upper airway disease (SCUAD)]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2017</year>
<volume>124</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>428-33</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fahrenholz]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural history and clinical features of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Clin Rev Allergy Immunol]]></source>
<year>2003</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>113-24</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Stoner]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Borish]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future]]></article-title>
<source><![CDATA[Am J Rhinol Allergy]]></source>
<year>2016</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>407-13</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[De-Bruïne]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Van-Buchem MA]]></given-names>
</name>
<name>
<surname><![CDATA[Sterk]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rabe]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Bel]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic sinusitis in severe asthma is related to sputum eosinophilia]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2002</year>
<volume>109</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>621-6</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woessner]]></surname>
<given-names><![CDATA[KM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Curr Allergy Asthma Rep]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dursun]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Woessner]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Karasoy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps , and chronic sinusitis]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2008</year>
<volume>100</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>420-5</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[RU]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory disease: Evaluation and management]]></article-title>
<source><![CDATA[Allergy Asthma Immunol Res]]></source>
<year>2011</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nizankowska-Mogilnicka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bochenek]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mastalerz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2007</year>
<volume>62</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1111-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mirakian]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Larco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sannah]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Darby]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nasal lysine aspirin challenge in the diagnosis of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Clin Exp Allergy]]></source>
<year>2013</year>
<volume>43</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>874-80</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bigby]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2006</year>
<volume>97</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>190-5</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrera-Morales]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Cardona-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Henao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Holguín-Gómez]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Giraldo]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Chinchilla-Mejía]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of meloxicam oral provocation challenge in patients with NSAID reaction]]></article-title>
<source><![CDATA[World Allergy Organ J]]></source>
<year>2015</year>
<volume>8</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patrono]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[FitzGerald]]></surname>
<given-names><![CDATA[GA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The coxibs, selective inhibitors of cyclooxygenasse-2]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>433-42</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warner]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vojnovic]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bukasa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vane]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>1999</year>
<volume>96</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>7563-8</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Knaus]]></surname>
<given-names><![CDATA[EE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond]]></article-title>
<source><![CDATA[J Pharm Pharm Sci]]></source>
<year>2008</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-110</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walgama]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[PH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Otolaryngol Clin North Am]]></source>
<year>2017</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>83-94</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parnes]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Chuma]]></surname>
<given-names><![CDATA[AV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute effects of antileukotrienes on sinonasal polyposis and sinusitis]]></article-title>
<source><![CDATA[Ear Nose Throat J]]></source>
<year>2000</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-20:24-25</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wentzel]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[DeYoung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Lohia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schlosser]]></surname>
<given-names><![CDATA[RJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Leukotriene antagonists in nasal polyposis: A meta-analysis and systematic review]]></article-title>
<source><![CDATA[Am J Rhinol Allergy]]></source>
<year>2013</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>482-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergmann]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Zuberbier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Church]]></surname>
<given-names><![CDATA[MK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in the treatment of aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2015</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>459-60</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porcaro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Di-Marco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cutrera]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria]]></article-title>
<source><![CDATA[Pediatr Pulmonol]]></source>
<year>2017</year>
<volume>52</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>E26-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phillips-Angles]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barranco]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lluch-Bernal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez-Ortega]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López-Carrasco]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Quirce]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2017</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>842-5</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gevaert]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Calus]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Van-Zele]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Blomme]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[De-Ruyck]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bauters]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2013</year>
<volume>131</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>110-6</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Holtappels]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gevaert]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Patou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dhaliwal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gould]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucosal tissue polyclonal IgE is functional in response to allergen and SEB]]></article-title>
<source><![CDATA[Allergy]]></source>
<year>2011</year>
<volume>66</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>141-8</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mitsui]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nakatani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fukutomi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kajiwara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Watai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omalizumab reduces cysteinyl leukotriene and 9&#945;11&#946; prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2016</year>
<volume>137</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1585-7</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardona-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Diez-Zuluaga]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Giraldo]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Caraballo]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Desensibilización al ácido acetil-salicílico como tratamiento para la enfermedad respiratoria exacerbada por antiinflamatorios no esteroides]]></article-title>
<source><![CDATA[Iatreia (Medellín)]]></source>
<year>2014</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>299-308</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardona-Villa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Reina]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alergia e intolerancia a antiinflamatorios no esteroides: desensibilización exitosa en tres casos y revisión de la literatura]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>181-90</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Soudry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Psaltis]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nadeau]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[McGhee]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Nayak]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease]]></article-title>
<source><![CDATA[Otolaryngol Head Neck Surg]]></source>
<year>2014</year>
<volume>151</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>2-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortellini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Romano]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspirin challenge and desensitization: How, when and why]]></article-title>
<source><![CDATA[Curr Opin Allergy Clin Immunol]]></source>
<year>2017</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>247-54</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berges-Gimeno]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Stevenson]]></surname>
<given-names><![CDATA[DD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2003</year>
<volume>111</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>180-6</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waldram]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Performing aspirin desensitization in aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[Immunol Allergy Clin North Am]]></source>
<year>2016</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>693-703</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steinke]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Culp]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Kropf]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Borish]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2009</year>
<volume>124</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>724-30</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Buchmiller]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2015</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>926-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
